MCID: CLT003
MIFTS: 62

Colitis

Categories: Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 11 75 28 53 5 43 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0060180
MeSH 43 D003092
NCIt 49 C26723
SNOMED-CT 68 64226004
ICD10 31 K52.9
UMLS 71 C0009319

Summaries for Colitis

Disease Ontology: 11 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary: Colitis is related to ulcerative colitis and inflammatory bowel disease 1. An important gene associated with Colitis is SYK (Spleen Associated Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Magnesium citrate and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include colon, bone marrow and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Wikipedia: 75 Colitis is swelling or inflammation of the large intestine (colon). Colitis may be acute and... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2105)
# Related Disease Score Top Affiliating Genes
1 ulcerative colitis 33.9 TNF TLR2 ST6GALNAC1 NOD2 MPO IL4
2 inflammatory bowel disease 1 33.7 TNF TLR2 NOD2 IL23R IL1B IL17A
3 collagenous colitis 33.5 TNF MPO IL17A
4 microscopic colitis 33.4 TNF IL1B IL17A IL10
5 crohn's disease 33.3 TNF TLR2 NOD2 IL4 IL23R IL2
6 chemical colitis 33.2 TNF NOD2 IL1B IL17A IL10
7 inflammatory bowel disease 33.1 TNF TLR2 ST6GALNAC1 NOD2 MPO IL4
8 crohn's colitis 33.0 TNF NOD2 IL1B IL17A IL10 ATG16L1
9 amebiasis 32.9 TNF TLR2 IL4 IL1B IL17A IL10
10 cholangitis, primary sclerosing 32.6 TNF NOD2 MPO IL4 IL1B IL17A
11 bowel dysfunction 32.6 TNF NOD2 IL1B IL10
12 pouchitis 32.6 TNF NOD2
13 diarrhea 32.6 TNF NOD2 MPO IL2 IL1B IL13
14 gastroenteritis 32.6 TNF IL4 IL1B IL10 IFNG
15 enterocolitis 32.6 TNF NOD2 IL10
16 pyoderma gangrenosum 32.4 TNF NOD2 IL1B
17 spondyloarthropathy 1 32.4 TNF NOD2 IL23R IL1B IL17A IL10
18 cholangitis 32.3 TNF NOD2 MPO IL2 IL17A IL10
19 inflammatory bowel disease 25, autosomal recessive 32.3 IL10RB IL10
20 common cold 32.3 TNF IL4 IL2 IL1B IL17A IL13
21 sclerosing cholangitis 32.1 TNF IL17A IL10
22 ileitis 32.1 TNF TLR2 NOD2 MPO IL17A IL10
23 irritable bowel syndrome 32.0 TNF TLR2 IL4 IL1B IL17A IL10
24 autoimmune disease 32.0 TNF IL4 IL23R IL2 IL1B IL17A
25 pyoderma 32.0 TNF NOD2 IL1B IL17A
26 celiac disease 1 31.9 TNF TLR2 NOD2 IL4 IL23R IL2
27 vasculitis 31.9 TNF MPO IL1B IL17A IL10 HLA-DRB1
28 proteasome-associated autoinflammatory syndrome 1 31.8 TNF TLR2 MPO IL4 IL1B IL17A
29 hypereosinophilic syndrome 31.8 MPO IL4 IL2 IL13 IL10 IFNG
30 colonic benign neoplasm 31.8 TNF IL1B IL17A IL10 FOXP3 CTNNB1
31 peritonitis 31.8 TNF TLR2 NOD2 MPO IL1B IL17A
32 human cytomegalovirus infection 31.8 TNF IL17A IL10
33 severe combined immunodeficiency 31.8 TNF IL4 IL2 IL17A IL13 IL10
34 appendicitis 31.7 TNF MPO IL2 IL1B IL17A IL10
35 dysentery 31.7 TNF IL1B IL10
36 gastritis 31.7 TNF IL4 IL1B IL17A IL10
37 ileocolitis 31.7 TNF NOD2 ATG16L1
38 ileus 31.7 TNF IL1B IL17A IL10 IFNG
39 salmonellosis 31.7 TNF TLR2 NOD2 IL4 IL1B IL17A
40 deficiency anemia 31.6 TNF IL2 IL1B IL10 FOXP3
41 purpura 31.6 TNF IL4 IL2 IL1B IL17A IL10
42 acquired immunodeficiency syndrome 31.6 TNF IL2 IL1B IL10 IFNG
43 erythema nodosum 31.6 TNF NOD2 IL1B IL13 IL10 IFNG
44 spondylitis 31.6 TNF NOD2 IL23R IL1B IL17A IL10
45 graft-versus-host disease 31.5 TNF IL2 IL10 IFNG
46 exanthem 31.5 TNF MPO IL4 IL2 IL1B IL17A
47 typhoid fever 31.5 TNF IL1B IFNG HLA-DRB1
48 toxic shock syndrome 31.5 TNF TLR2 IL4 IL2 IL1B IL10
49 acute pancreatitis 31.5 TNF MPO IL1B IL10
50 takayasu arteritis 31.5 TNF IL23R IL10 HLA-DRB1

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 ATG16L1 CHEK2 CTNNB1 FOXP3 HLA-DRB1 IFNG
2 no effect GR00402-S-2 10.15 ATG16L1 CHEK2 CTNNB1 FOXP3 HLA-DRB1 IFNG
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.07 IL10 IL17A IL1B MPO TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.07 IL10 IL17A IL1B IL2 MPO NOD2
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.07 CHEK2

MGI Mouse Phenotypes related to Colitis:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
2 growth/size/body region MP:0005378 10.45 ATG16L1 CTNNB1 FOXP3 HLA-DRB1 IFNG IL10
3 endocrine/exocrine gland MP:0005379 10.41 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
4 immune system MP:0005387 10.36 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
5 digestive/alimentary MP:0005381 10.34 ATG16L1 CTNNB1 FOXP3 IFNG IL10 IL10RB
6 no phenotypic analysis MP:0003012 10.31 CTNNB1 FOXP3 IFNG IL10 IL13 IL17A
7 cellular MP:0005384 10.3 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
8 liver/biliary system MP:0005370 10.29 CTNNB1 FOXP3 IFNG IL10 IL10RB IL17A
9 neoplasm MP:0002006 10.23 CHEK2 CTNNB1 IFNG IL10 IL1B IL2
10 cardiovascular system MP:0005385 10.21 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
11 muscle MP:0005369 10.16 ATG16L1 CTNNB1 IFNG IL10 IL13 MPO
12 respiratory system MP:0005388 10.15 CTNNB1 FOXP3 IFNG IL10 IL10RB IL13
13 hematopoietic system MP:0005397 10.11 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
14 craniofacial MP:0005382 10.08 CTNNB1 FOXP3 IFNG IL10 IL17A IL1B
15 reproductive system MP:0005389 10.06 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
16 skeleton MP:0005390 10.03 CTNNB1 HLA-DRB1 IFNG IL10 IL13 IL17A
17 mortality/aging MP:0010768 9.89 ATG16L1 CHEK2 CTNNB1 FOXP3 IFNG IL10
18 integument MP:0010771 9.36 ATG16L1 CTNNB1 FOXP3 IFNG IL10 IL13

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium citrate Approved Phase 4 3344-18-1
2
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Iron Approved Phase 4 7439-89-6 29936
5
Linaclotide Approved Phase 4 851199-59-2 16158208
6
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
9
Certolizumab pegol Approved Phase 4 428863-50-7
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
15
Golimumab Approved Phase 4 476181-74-5
16
Ozanimod Approved, Investigational Phase 4 1306760-87-1 25110515 52938427
17
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
18
Azathioprine Approved Phase 4 446-86-6 2265
19
Infliximab Approved Phase 4 170277-31-3
20
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
21
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
22
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
24 Cathartics Phase 4
25 Laxatives Phase 4
26 Picosulfate sodium Phase 4
27 Cyclosporins Phase 4
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
29 Iron Supplement Phase 4
30 Chrysarobin Phase 4
31 Hydrocortisone 17-butyrate 21-propionate Phase 4
32 polysaccharide-K Phase 4
33 glucocorticoids Phase 4
34
Methylprednisolone Acetate Phase 4 584547
35 Protective Agents Phase 4
36 Antineoplastic Agents, Hormonal Phase 4
37 Neuroprotective Agents Phase 4
38 Antiemetics Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Immunoglobulins Phase 4
41 Antibodies Phase 4
42 Dermatologic Agents Phase 4
43 Anti-Bacterial Agents Phase 4
44 Anti-Infective Agents Phase 4
45 Tumor Necrosis Factor Inhibitors Phase 4
46 Immunologic Factors Phase 4
47 Protein Kinase Inhibitors Phase 4
48 Anticonvulsants Phase 4
49 Tin Fluorides Phase 4
50 Immunoglobulins, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 1356)
# Name Status NCT ID Phase Drugs
1 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Unknown status NCT02687724 Phase 4 Golimumab (GLM)
2 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
3 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
4 Exposure-response of Golimumab During Maintenance in Ulcerative Colitis: An Exploratory Pharmacokinetics/Pharmacodynamics Comparison of Different Dose Regimens Unknown status NCT04156984 Phase 4 Golimumab Prefilled Syringe
5 Optimization of Golimumab Treatment in Ulcerative Colitis Unknown status NCT03669029 Phase 4 Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg;Golimumab treatment optimization.
6 Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab Unknown status NCT03151525 Phase 4 Azathioprine;Infliximab
7 Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial Unknown status NCT03581149 Phase 4 Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
8 Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis Unknown status NCT04006080 Phase 4
9 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
10 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
11 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
12 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
13 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
14 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
15 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
16 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
17 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
18 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
19 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Completed NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
20 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
21 An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study) Completed NCT02646657 Phase 4 Vedolizumab 300 mg
22 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
23 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
24 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
25 A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET) Completed NCT03029143 Phase 4 Vedolizumab IV
26 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
27 Use of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study Completed NCT02345733 Phase 4 Antibiotic cocktail
28 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
29 Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
30 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed NCT03124121 Phase 4 Golimumab
31 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
32 An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab. Completed NCT02318667 Phase 4
33 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
34 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
35 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
36 A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment. Completed NCT04969679 Phase 4 E. coli Nissle 1917 (Mutaflor®);Placebo
37 Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. Completed NCT01536535 Phase 4 Mesalazine;IV Corticosteroid;Oral Corticosteroids
38 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
39 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
40 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine
41 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
42 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
43 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
44 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
45 A Clinical Trial for the Off Label Use of Ursodiol for the Prevention of Recurrent C. Difficile Colitis and Diarrhea Completed NCT02748616 Phase 4 Ursodiol
46 Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial Completed NCT04775732 Phase 4
47 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
48 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
49 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
50 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 28

Anatomical Context for Colitis

Organs/tissues related to Colitis:

FMA: Colon
MalaCards : Colon, Bone Marrow, T Cells, Small Intestine, Bone, Monocytes, Myeloid

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 30215)
# Title Authors PMID Year
1
Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. 53 62
20440854 2010
2
Colitis as a manifestation of infliximab-associated disseminated cryptococcosis. 53 62
19660974 2010
3
On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. 53 62
20144954 2010
4
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. 53 62
20181893 2010
5
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. 53 62
20004202 2010
6
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 53 62
20228197 2010
7
TLR5 is not required for flagellin-mediated exacerbation of DSS colitis. 53 62
19774646 2010
8
Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. 53 62
20008145 2010
9
A feed-forward loop involving hyaluronic acid and toll-like receptor-4 as a treatment for colitis? 53 62
19879211 2009
10
The gut feeling of Treg cells: IL-10 is the silver lining during colitis. 53 62
19841645 2009
11
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. 53 62
19104936 2009
12
Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. 53 62
19450685 2009
13
All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. 53 62
19477911 2009
14
An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. 53 62
19616541 2009
15
Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. 53 62
19535420 2009
16
Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. 53 62
19326358 2009
17
Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. 53 62
19446544 2009
18
Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. 53 62
19525396 2009
19
Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons. 53 62
19470777 2009
20
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. 53 62
19359427 2009
21
Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. 53 62
19403332 2009
22
Genomic analysis of sulfasalazine effect in experimental colitis is consistent primarily with the modulation of NF-kappaB but not PPAR-gamma signaling. 53 62
19365232 2009
23
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. 53 62
19285099 2009
24
Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Ca2+ sensitization in murine experimental colitis. 53 62
19190174 2009
25
Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. 53 62
19250273 2009
26
Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis. 53 62
19238344 2009
27
Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. 53 62
19342675 2009
28
Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. 53 62
19238529 2009
29
Tumor necrosis factor-alpha impairs intestinal phosphate absorption in colitis. 53 62
19196948 2009
30
Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. 53 62
19126671 2009
31
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. 53 62
18612822 2009
32
Protection from DNBS-induced colitis by the tachykinin NK(1) receptor antagonist SR140333 in rats. 53 62
19103194 2009
33
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. 53 62
18815359 2009
34
Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. 53 62
19101538 2009
35
Dietary taurine attenuates dextran sulfate sodium (DSS)-induced experimental colitis in mice. 53 62
19239157 2009
36
The beneficial effect of Rheum tanguticum polysaccharide on protecting against diarrhea, colonic inflammation and ulceration in rats with TNBS-induced colitis: the role of macrophage mannose receptor in inflammation and immune response. 53 62
18790466 2008
37
Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. 53 62
18818316 2008
38
Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. 53 62
18618633 2008
39
Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. 53 62
18827968 2008
40
Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis. 53 62
18667332 2008
41
Blockade of adenosine A2B receptors ameliorates murine colitis. 53 62
18536750 2008
42
Treatment of severe steroid refractory ulcerative colitis. 53 62
18810767 2008
43
Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. 53 62
18599605 2008
44
Tumour necrosis factor alpha in segmental colitis associated with diverticula. 53 62
18049899 2008
45
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. 53 62
18535667 2008
46
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. 53 62
18381351 2008
47
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. 53 62
18473420 2008
48
Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. 53 62
18334870 2008
49
Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. 53 62
18400195 2008
50
Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. 53 62
18202111 2008

Variations for Colitis

ClinVar genetic disease variations for Colitis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SYK NM_003177.7(SYK):c.1649C>T (p.Ser550Phe) SNV Pathogenic
989386 rs1828636794 GRCh37: 9:93650098-93650098
GRCh38: 9:90887816-90887816
2 SYK NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr) SNV Pathogenic
989389 rs1828636794 GRCh37: 9:93650098-93650098
GRCh38: 9:90887816-90887816
3 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs) DEL Pathogenic
128042 rs555607708 GRCh37: 22:29091857-29091857
GRCh38: 22:28695869-28695869
4 SYK NM_003177.7(SYK):c.1024C>A (p.Pro342Thr) SNV Likely Pathogenic
989387 rs1827861920 GRCh37: 9:93636974-93636974
GRCh38: 9:90874692-90874692
5 SYK NM_003177.7(SYK):c.1350G>A (p.Met450Ile) SNV Likely Pathogenic
989237 rs1304839707 GRCh37: 9:93640021-93640021
GRCh38: 9:90877739-90877739
6 SYK NM_003177.7(SYK):c.1057G>A (p.Ala353Thr) SNV Uncertain Significance
989236 rs200167353 GRCh37: 9:93637007-93637007
GRCh38: 9:90874725-90874725
7 CIITA NM_000246.4(CIITA):c.3344G>A (p.Ser1115Asn) SNV Uncertain Significance
598994 rs138790505 GRCh37: 16:11017111-11017111
GRCh38: 16:10923254-10923254
8 FLNA NM_001110556.2(FLNA):c.7463C>A (p.Thr2488Asn) SNV Uncertain Significance
465020 rs909387820 GRCh37: X:153578106-153578106
GRCh38: X:154349738-154349738

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CTNNB1 HLA-DRB1 IFNG IL10 IL10RB IL13
2
Show member pathways
13.89 TNF IL4 IL23R IL2 IL1B IL17A
3
Show member pathways
13.7 TNF IL4 IL23R IL2 IL1B IL17A
4
Show member pathways
13.6 IFNG IL10 IL10RB IL13 IL17A IL1B
5
Show member pathways
13.52 CTNNB1 IFNG IL1B IL2 IL4 SYK
6
Show member pathways
13.5 IL10 IL10RB IL13 IL17A IL1B IL2
7
Show member pathways
13.4 CTNNB1 IL10 IL10RB IL13 IL17A IL1B
8
Show member pathways
13.37 TNF SYK NOD2 IL4 IL23R IL2
9
Show member pathways
12.86 TNF TLR2 SYK IL2 IL1B
10
Show member pathways
12.75 IFNG IL10 IL10RB IL13 IL17A IL1B
11
Show member pathways
12.66 TNF MPO IL23R IL2 IL1B IL17A
12 12.62 FOXP3 IFNG IL10 IL17A IL1B IL2
13
Show member pathways
12.53 TNF TLR2 NOD2 IL1B
14
Show member pathways
12.52 IL2 IL1B IL13 CTNNB1 CHEK2
15
Show member pathways
12.5 TNF TLR2 IL4 IL1B IFNG
16
Show member pathways
12.3 TNF SYK IL4 IL2 IFNG
17
Show member pathways
12.28 HLA-DRB1 IFNG IL10 IL17A IL2 IL23R
18 12.27 TNF IL1B IL13 IL10 CTNNB1
19 12.26 TNF IL4 IL1B IL13 IL10RB IL10
20 12.24 TNF TLR2 IFNG CTNNB1
21 12.15 TNF MPO IL4 IL2 IL10 IFNG
22
Show member pathways
12.13 SYK IL4 IL2 IFNG FOXP3
23 12.11 TNF IL4 IL2 IL1B IFNG
24 12.11 TNF IL4 IL23R IL1B IL17A IL13
25
Show member pathways
12.1 TLR2 IL2 IL1B IL13
26
Show member pathways
12.06 IL4 IL2 IL1B IFNG
27
Show member pathways
12.03 IFNG IL17A IL1B IL23R IL4 TLR2
28
Show member pathways
12.01 IFNG IL10 IL17A IL1B IL2 IL23R
29 11.99 FOXP3 HLA-DRB1 IFNG IL10 IL13 IL17A
30 11.91 TNF SYK IL4 IL2 IL10 IFNG
31 11.9 TNF IL2 IL1B IL10 IFNG
32
Show member pathways
11.88 IL23R IL17A FOXP3
33 11.88 IL4 IL2 IL13 IFNG
34 11.86 IL4 IL2 IL10 IFNG CTNNB1
35
Show member pathways
11.85 TNF IL4 IL2 IFNG FOXP3
36 11.84 IL4 IL23R IL2 IL1B IL17A IFNG
37
Show member pathways
11.81 TNF IL1B IFNG
38 11.79 IL13 IL1B IL4 TNF
39
Show member pathways
11.79 IFNG IL1B IL2 TNF
40 11.78 IL2 IL10 IFNG
41 11.77 TNF IL1B IL10RB IL10
42
Show member pathways
11.73 FOXP3 IFNG IL10 IL13 IL2 IL23R
43 11.71 IFNG IL10 IL13 IL17A IL1B IL2
44 11.7 TNF IL4 IL2 IL10RB IL10 IFNG
45 11.66 IL4 IL2 IL13 IL10 IFNG FOXP3
46 11.64 TNF TLR2 IL1B IFNG
47 11.63 IL10 IL10RB IL1B TNF
48 11.61 TNF NOD2 IFNG
49
Show member pathways
11.56 TNF IL2 IL10 IFNG FOXP3
50 11.55 TNF IL1B IFNG

GO Terms for Colitis

Biological processes related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.63 CTNNB1 FOXP3 IL10 IL17A IL1B IL2
2 positive regulation of DNA-templated transcription GO:0045893 10.59 CHEK2 CTNNB1 FOXP3 HLA-DRB1 IL10 IL1B
3 negative regulation of cell population proliferation GO:0008285 10.47 TNF TLR2 IL1B IL10 FOXP3 CTNNB1
4 positive regulation of gene expression GO:0010628 10.4 CTNNB1 FOXP3 IFNG IL13 IL1B IL4
5 inflammatory response GO:0006954 10.4 TNF TLR2 IL23R IL1B IL17A IL13
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.39 TNF NOD2 IL1B HLA-DRB1 CTNNB1
7 defense response to bacterium GO:0042742 10.37 TNF SYK NOD2 MPO IL10
8 positive regulation of protein phosphorylation GO:0001934 10.37 TNF IL2 IL1B HLA-DRB1 CHEK2
9 positive regulation of DNA-binding transcription factor activity GO:0051091 10.34 CTNNB1 IL10 IL1B TNF
10 MAPK cascade GO:0000165 10.29 TNF NOD2 IL1B CTNNB1
11 positive regulation of type II interferon production GO:0032729 10.28 TNF IL23R IL2 IL1B
12 negative regulation of tumor necrosis factor production GO:0032720 10.28 FOXP3 IL10 IL4 NOD2
13 positive regulation of MAPK cascade GO:0043410 10.28 TNF SYK NOD2 HLA-DRB1 CTNNB1
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.27 IL1B NOD2 TLR2 TNF
15 positive regulation of interleukin-1 beta production GO:0032731 10.27 TNF NOD2 IL17A IFNG
16 defense response to Gram-positive bacterium GO:0050830 10.26 IL17A IL1B NOD2 TLR2 TNF
17 positive regulation of inflammatory response GO:0050729 10.26 TNF TLR2 IL2 IL1B IFNG
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.25 CTNNB1 IL1B NOD2 TNF
19 positive regulation of tumor necrosis factor production GO:0032760 10.25 TLR2 SYK NOD2 IL17A IFNG
20 negative regulation of inflammatory response GO:0050728 10.24 IL4 IL2 IL13 IL10 FOXP3
21 regulation of insulin secretion GO:0050796 10.23 TNF IL1B IFNG
22 positive regulation of B cell proliferation GO:0030890 10.23 IL4 IL2 IL13
23 negative regulation of T cell proliferation GO:0042130 10.22 FOXP3 HLA-DRB1 IL10
24 positive regulation of nitric oxide biosynthetic process GO:0045429 10.22 TNF IL1B IFNG
25 lipopolysaccharide-mediated signaling pathway GO:0031663 10.21 TNF TLR2 IL1B
26 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.21 TNF IL10RB IL10
27 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.21 IL4 IL2 IL1B
28 positive regulation of phagocytosis GO:0050766 10.21 TNF NOD2 IL1B IFNG
29 negative regulation of endothelial cell apoptotic process GO:2000352 10.2 IL4 IL13 IL10
30 positive regulation of T cell proliferation GO:0042102 10.2 IL4 IL23R IL2 IL1B
31 immune system process GO:0002376 10.2 TLR2 SYK NOD2 IL23R IL2 IL17A
32 positive regulation of immunoglobulin production GO:0002639 10.18 IL2 IL13 IL10
33 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.18 TNF NOD2 IL17A
34 positive regulation of interleukin-17 production GO:0032740 10.18 NOD2 IL23R IL2
35 negative regulation of inflammatory response to antigenic stimulus GO:0002862 10.18 HLA-DRB1 NOD2 SYK
36 negative regulation of type II interferon production GO:0032689 10.18 NOD2 IL10 HLA-DRB1 FOXP3
37 positive regulation of interleukin-8 production GO:0032757 10.16 TNF TLR2 SYK NOD2 IL1B
38 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.15 TLR2 NOD2 IFNG
39 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.15 IFNG IL13 IL2 IL23R IL4 TNF
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.14 TNF IL1B IFNG
41 positive regulation of chemokine production GO:0032722 10.13 TNF TLR2 IL1B IFNG
42 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.12 TNF IL1B IL10
43 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 10.12 SYK IL23R IL1B
44 positive regulation of monocyte chemotactic protein-1 production GO:0071639 10.11 SYK NOD2 IL1B
45 astrocyte activation GO:0048143 10.11 TNF IL1B IFNG
46 positive regulation of cytokine production GO:0001819 10.11 TNF SYK IL1B IL10 IFNG
47 negative regulation of neurogenesis GO:0050768 10.1 TNF IL1B CTNNB1
48 positive regulation of MHC class II biosynthetic process GO:0045348 10.1 IL4 IL10 IFNG
49 positive regulation of interleukin-10 production GO:0032733 10.1 TLR2 SYK NOD2 IL4 IL13
50 positive regulation of interleukin-6 production GO:0032755 10.1 TNF TLR2 SYK NOD2 IL1B IL17A

Molecular functions related to Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.53 TNF IL4 IL2 IL1B IL17A IL13
2 Toll-like receptor binding GO:0035325 9.26 TLR2 SYK

Sources for Colitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....